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Sir,
Situated in South Asia, Pakistan is a home to over 180
million populations. With a carrier rate of 5% to 13% in
the country,1 an estimated 5000 to 9000 children are
born annually with beta-thalassemia major. Bone
marrow transplantation is expensive and restricted to a
couple of large cities, therefore, majority of children are
treated with regular blood transfusions.
Excess iron from transfusions deposits in liver, heart and
endocrine glands leading to organ failures if not
controlled and eliminated by chelation therapy.2
Deferoxamine, the parent drug in use for last four
decades requires parenteral administration whereas,
deferiprone although orally active and well proven to be
cardioprotective,3 requires thrice daily administration
and may cause idiosyncratic reactions like erosive
arthritis and agranulocytosis.3 These facts are the
reasons for non-compliance and hence poor iron
chelation. After the availability of deferasirox in Pakistan
in 2008, physicians and patients considered it as an
answer to their miseries. It is orally active and has
bioavailability and half-life suitable for once daily
dosing.4 The most common side effects reported with
deferasirox are gastro-intestinal events, skin rash and
mild dose-dependent increase in creatinine and hepatic
transaminase levels.
Our institute has a day-care centre which offers blood
transfusion facilities to over 200 thalassemia major
patients. Several thalassemics were started on
deferasirox however, many of them discontinued it
because of its questionable efficacy. Serum ferritin levels
did not improve substantially in several patients. As it
was a significant observation, we evaluated the efficacy
of deferasirox in these patients. Thalassemics were
included who reported a good compliance with the
medicine and were free from any liver disease. Baseline
serum ferritin levels (before starting deferasirox), dose of
deferasirox, last available ferritin levels and duration of
treatment were inquired and confirmed from medical
records. For assessment of hepatic and renal functions,
Alanine Aminotransferase (ALT) and serum creatinine
levels respectively were performed before starting the
drug and thence repeated at a variable time period of
1 - 6 months. Complete blood counts were evaluated for
cytopenias before each transfusion (at 3 - 4 weeks
interval). Furthermore, patients were examined for
auditory, ocular, cardiac and gastrointestinal disturban-
ces at their visits to outpatient clinic or in the day-care.
Due to unavailability of more sophisticated methods like
T2*MRI and Superconducting Quantum Interference
Device (SQUID), serum ferritin level was used to assess
reduction in iron overload. Parents/guardians of all
patients were counselled in detail regarding possible
benefits and adverse effects of deferasirox. All the
patients were provided liberty to stop or change the
medicine at any time.
A total of 63 patients were included for analysis. The
mean age was 12.2 ± 7.2 years with male: female ratio
of 1:1. The mean serum ferritin level before starting
deferasirox was 5254.5 ± 3540.4 ng/ml (range 1276 -
19265) whereas it was 4701.8 ± 2989.8 ng/ml (range
538 - 17200) at the time of final analysis. The application
of paired-samples T-test showed a difference of -552.7 ±
1677.2 ng/ml (p=0.01). The mean duration of the
medicinal intake was 15.2 ± 15.9 months (range 5 - 65
months) and the mean dose of deferasirox was 22.9 ±
7.5 mg/kg/day. Ten (16%) patients reported gastro-
intestinal disturbance mostly in first few weeks of starting
the drug. No patient developed skin rash. Hepatic, renal,
ocular, auditory and cardiac abnormalities were not
observed in any patient.
High serum ferritin level in the study cohort reflects the
poor iron chelation in majority of thalassemics in our
country.5 Nevertheless in current analysis, deferasirox
resulted in decrease in ferritin levels with continued use
(p=0.01) without any major untoward adverse effect. In
search of an ideal iron chelator, the availability of
deferasirox generated a hope for proper management
and hence, better lifestyle for thalassemia major
patients. Based on this observation and its concordance
with the literature,4 we recommend the continued use of
deferasirox in patients with thalassemia major
particularly in those who are non-compliant with other
regimens.
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